2023-508567-75-00
Not yet recruiting
Phase 1/2
Prospective pilot study, assessing imaging performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Patients with HepatoCellular Carcinoma, IntraHepatic CholangioCarcinoma or Gastro-Entero-Pancreatic Neuroendocrine Neoplasms.
Centre Hospitalier Universitaire De Nantes2 sites in 1 country60 target enrollmentStarted: November 27, 2024Last updated:
Overview
- Phase
- Phase 1/2
- Status
- Not yet recruiting
- Sponsor
- Centre Hospitalier Universitaire De Nantes
- Enrollment
- 60
- Locations
- 2
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Dr Clément BAILLY
Scientific
Centre Hospitalier Universitaire De Nantes
Study Sites (2)
Loading locations...
Similar Trials
Active, not recruiting
Phase 1
Imaging study evaluating the utility of pre-treatment zirconium-89 labelled trastuzumab PET/CT (Imaging of the membranair receptor HER2 with the tracer zirconium 89 trastuzumab) and an early FDG-PET/CT response (early metabolic assessment) to identify patients with HER-2 positive invasive carcinoma of the breast with locally recurrent (not amenable to resection with curative intent) or metastatic disease unlikely to benefit from a novel anti-HER2 therapy: T-DM1EUCTR2011-005437-39-BEJules Bordet Institute105
Active, not recruiting
Phase 1
Imaging study evaluating the utility of pre-treatment zirconium-89 labelled trastuzumab PET/CT (Imaging of the membranair receptor HER2 with the tracer zirconium 89 trastuzumab) and an early FDG-PET/CT response (early metabolic assessment) to identify patients with HER-2 positive invasive carcinoma of the breast with locally recurrent (not amenable to resection with curative intent) or metastatic disease unlikely to benefit from a novel anti-HER2 therapy: T-DM1ocally recurrent (not amenable to resection with curative intent) or metastatic disease scheduled for a first or any subsequent metastatic treatment lineMedDRA version: 19.0Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-005437-39-NLJules Bordet Institute105
Completed
Phase 2
A phase II prospective imaging study evaluating the utility of pre-treatment zirconium-89 labelled trastuzumab PET/CT and an early FDG-PET/CT response to identify patients with advanced HER-2 positive breast cancer unlikely to benefit from a novel anti-HER2 therapy: T-DM1HER2 positive breast cancerBreast cancer10006291NL-OMON43903Institut Jules Bordet55
Recruiting
Not Applicable
Determining the Benefits of Exercise on Cardiovascular Risk in PTSDNCT07260032Massachusetts General Hospital10
Not yet recruiting
Not Applicable
Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for GlioblastomaNCT07274397Beta Emitting Accurate Monitored Systems15